DezapelisibAlternative Names: INCB-40093; INCB040093
Latest Information Update: 12 Dec 2016
At a glance
- Originator Incyte Corporation
- Class Antineoplastics; Purines; Pyrimidinones; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hodgkin's disease; Non-Hodgkin's lymphoma